A disclaimer that disclaims the seller
Trademark disclaimers on sites like this normally list the manufacturers of the approved drugs and say the seller is not affiliated with them. This one names a company carrying the seller's own brand and says exactly that about it.
That is the shape of a template where a brand name was substituted into the wrong slot. Whatever caused it, the effect is that the single sentence on the site that names a corporate entity is the sentence saying the site is not connected to it.
No operating company can be read off that page, and none appears elsewhere. We have recorded no entity rather than treating a disclaimer as an identification.
Two prices, one sale, one end date
A navigation band on every page, legal pages included, advertises a sale with a figure for each drug and a stated end date. An article on the same site prices the semaglutide programme from a lower-to-higher figure on a six-month plan, with a free provider visit, free shipping and free supplies listed.
The sale figures are lower than the plan figures. Both are the seller's own and both are current. Our record carries all four rows, with the surface and the sale's end date written into the qualifiers.
Putting an end date on a sale is better practice than the undated permanent discount that runs on much of this roster, and it also means a reader arriving after that date should expect the plan figures instead.
The address that was asked for is not the address that answered
The article carrying the plan prices was requested at one path and served at another on the same host, with a different suffix appended. The redirect is silent and the content is the article that was wanted.
It is recorded because a same-host path rewrite is exactly the case where a link, a citation or an automated check can quietly describe a page that no longer lives where it was found. The source URL on this row is the effective path, not the requested one.
The article states that the programme is one payment with no membership, which is why the membership position here is recorded as none. No pharmacy, no clinician and no service area is published.
CoraDoc's published pricing
| Medication | Price | Verified |
|---|---|---|
| Semaglutide (compounded) | $99/mofrom, on a six-month plan, quoted as "Compounded Semaglutide programs from $99/month on a 6-month plan" with a free provider visit, free two-day shipping and free supplies | September 2026source |
| Tirzepatide (compounded) | $149/mofrom, quoted in the same sentence as the semaglutide six-month figure | September 2026source |
| Semaglutide (compounded) | $77/moa dated sale figure carried in the site-wide navigation on every page, including the terms and the privacy policy: "BIGGEST GLP-1 SALE IN AMERICA - Semaglutide $77/mo - Tirzepatide $127/mo - Ends Tuesday, Sept 8" | September 2026source |
| Tirzepatide (compounded) | $127/mothe tirzepatide half of the same dated sale banner, with the same stated end date | September 2026source |
compareglp may earn a commission when a reader signs up with a provider through a link on this site. 4 of the 158 providers reviewed here are paid partners today; the other 154 are not. See how this works.
See CoraDoc's current price →Good fit if
- Readers who want a sale with a stated end date rather than a permanent discount.
- Buyers who want the plan term printed beside the cheaper figure, which the article does.
- People comparing a dated promotion against a plan rate from the same seller.
Look elsewhere if
- Anyone who wants to know which company they are buying from.
- Buyers arriving after the stated sale date, who should expect the higher plan figures.
- Readers who need the pharmacy or the prescriber named.
- People who need a published service area.
How this review was verified
- Read the Terms and the priced article on 6 September 2026, comparing requested to effective paths, and recorded that the article path was rewritten by the host.
- Ran a nonsense-path control on the same host in the same run, which returned a clean not-found status.
- Quoted the trademark disclaimer from the Terms verbatim before concluding that no operator is published, rather than treating the company name in it as an identification.
- Recorded the sale's stated end date in the qualifier of both sale rows so the figures age visibly.
- Screened the operating entity and the brand name against FDA's live warning-letter datatable, carrying a known letter as a positive control and a nonsense string as a negative control in the same pass; the positive control returned its letter and the negative returned nothing. Neither the entity nor the brand returned one. Untitled letters are published separately and were not searched, so the supportable claim is that no warning letter was found.